Trial · NCT03728504

Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema

NCT03728504, Phase 2, Completed, Asana BioSciences; results first posted 2023-05-09

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema. Trials, record NCT03728504. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03728504

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema
NCT number: NCT03728504
Status: Completed
Phases: Phase 2
Enrollment: 97 participants, actual
Lead sponsor: Asana BioSciences
Conditions: Chronic Hand Dermatitis
Interventions: ASN002, Placebo Oral Tablet
First posted: 2018-11-02
Last updated: 2023-05-09
Results first posted: 2023-05-09

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percent Change From Baseline in Modified Total Lesion Symptom Score (mTLSS)	16 weeks	Percent change from baseline in hand mTLSS at Week 16. The mTLSS is an assessment of the severity of each of the following: erythema, scaling, lichenification/hyperkeratosis, vesicles, edema, fissures, and pruritus/pain. Each of these are rated using a 4-point severity scale. The ratings are added to create a total mTLSS calculated as the sum of assigned individual scores with a maximum value of 21 (most severe disease) and a minimum of 0 (no disease)
Secondary	Change From Baseline in Hand Physician Global Assessment (PGA)	16 weeks	Proportion of participants with a response of Physicians Global Assessment achieving clear (0) or almost clear (1)
Secondary	Change From Baseline in Hand Patient Global Assessment (PaGA)	16 weeks	Reduction of PaGA compared to baseline where marked improvement was noted with at least 75% clear

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Percent Change From Baseline in Modified Total Lesion Symptom Score (mTLSS)	16 weeks	percentage change	MEAN
SECONDARY	Change From Baseline in Hand Physician Global Assessment (PGA)	16 weeks	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Change From Baseline in Hand Patient Global Assessment (PaGA)	16 weeks	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group9

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Percent Change From Baseline in Modified Total Lesion Symptom Score (mTLSS)	ASN002 40 mg	-49.5	Standard Deviation 40.65	percentage change
Percent Change From Baseline in Modified Total Lesion Symptom Score (mTLSS)	ASN002 80 mg	-71.3	Standard Deviation 26.97	percentage change
Percent Change From Baseline in Modified Total Lesion Symptom Score (mTLSS)	Placebo Oral Tablet	-29.9	Standard Deviation 38.51	percentage change
Change From Baseline in Hand Physician Global Assessment (PGA)	ASN002 40 mg	7		Participants
Change From Baseline in Hand Physician Global Assessment (PGA)	ASN002 80 mg	10		Participants
Change From Baseline in Hand Physician Global Assessment (PGA)	Placebo Oral Tablet	2		Participants
Change From Baseline in Hand Patient Global Assessment (PaGA)	ASN002 40 mg	7		Participants
Change From Baseline in Hand Patient Global Assessment (PaGA)	ASN002 80 mg	7		Participants
Change From Baseline in Hand Patient Global Assessment (PaGA)	Placebo Oral Tablet	2		Participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	ASN002 40 mg	33
Overall Study	STARTED	ASN002 80 mg	32
Overall Study	STARTED	Placebo Oral Tablet	32
Overall Study	COMPLETED	ASN002 40 mg	27
Overall Study	COMPLETED	ASN002 80 mg	19
Overall Study	COMPLETED	Placebo Oral Tablet	22
Overall Study	NOT COMPLETED	ASN002 40 mg	6
Overall Study	NOT COMPLETED	ASN002 80 mg	13
Overall Study	NOT COMPLETED	Placebo Oral Tablet	10

Source ClinicalTrials.gov

Adverse events255

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Upper respiratory tract infection	Infections and infestations	ASN002 40 mg	5	33
other	Upper respiratory tract infection	Infections and infestations	ASN002 80 mg	2	32
other	Upper respiratory tract infection	Infections and infestations	Placebo Oral Tablet	3	32
other	Nasopharyngitis	Infections and infestations	ASN002 40 mg	2	33
other	Nasopharyngitis	Infections and infestations	ASN002 80 mg	3	32
other	Nasopharyngitis	Infections and infestations	Placebo Oral Tablet	2	32
other	Headache	Nervous system disorders	ASN002 40 mg	5	33
other	Headache	Nervous system disorders	ASN002 80 mg	6	32
other	Headache	Nervous system disorders	Placebo Oral Tablet	1	32
other	Dizziness	Nervous system disorders	ASN002 40 mg	0	33

1 to 10 of 255Source ClinicalTrials.gov

See all 255 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	ASN002 40 mg	0	33
Total, all-cause mortality	ASN002 80 mg	0	32
Total, all-cause mortality	Placebo Oral Tablet	0	32
Total, other adverse events	ASN002 40 mg	19	33
Total, other adverse events	ASN002 80 mg	24	32
Total, other adverse events	Placebo Oral Tablet	17	32
Total, serious adverse events	ASN002 40 mg	0	33
Total, serious adverse events	ASN002 80 mg	2	32
Total, serious adverse events	Placebo Oral Tablet	1	32

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
39760239	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03728504

GET https://conductscience.org/api/trials/v1/NCT03728504/events?page=2

API reference For AI assistants